Frontiers in Psychiatry
September 18, 2023
Karina Sergi, Micah Linton, Rhianna Rich et al.
21 citations
Introduction Psychedelic-assisted therapy with psilocybin has shown promise in Phase 2 trials for alcohol use disorder (AUD). Set and setting, particularly factors facilitating a connection with nature, may positively influence the psychedelic experience and therapeutic outcomes. But to date, randomized controlled trials of interventions to enhance set and setting for psychedelic-assisted...
Frontiers in Psychiatry
August 24, 2023
Grant Jones, Patrick Mair, Maha Al-Suwaidi et al.
10 citations
Introduction Psilocybin use has been linked to lowered odds of crime-related outcomes across a host of observational studies. No studies have investigated how these associations may differ among those of different races and ethnicities. Methods Using a nationally-representative sample of 734,061 adults from the National Survey on Drug Use and Health (2002–2020), we investigated whether race and...
Frontiers in Psychiatry
August 4, 2023
Kasey Cox, Cody Weston, Moss Herberholz et al.
Introduction There is substantial public interest in psychedelics as potential treatments for psychiatric conditions. However, most psychedelics are criminalized under federal law in the USA, so it is unclear whether use occurs with clinical support. Our objective was to assess whether naturalistic psychedelic use occurs with clinical support, interactions between those using psychedelics and...
Frontiers in Psychiatry
July 15, 2023
M. Kati Lear, Sarah M. Smith, Brian Pilecki et al.
14 citations
BackgroundSocial anxiety disorder (SAD) is a serious and prevalent psychiatric condition that heavily impacts social functioning and quality of life. Though efficacious treatments exist for SAD, remission rates remain elevated and a significant portion of those affected do not access effective treatment, suggesting the need for additional evidence-based treatment options. This paper presents a...
Frontiers in Psychiatry
July 11, 2023
Gniewko Więckiewicz, Iga Stokłosa, Maciej Stokłosa et al.
2 citations
Introduction Attention-deficit/hyperactivity disorder (ADHD) was originally treated as a neurodevelopmental disorder that occurs mainly in children and tends to diminish or disappear with age, but we now know that symptoms persist into adulthood in over 50% of ADHD patients. Undiagnosed individuals often turn to psychoactive substance to minimize the negative aspects of functioning and improve...
Frontiers in Psychiatry
June 30, 2023
Colleen E. Charlton, Povilas Karvelis, Roger S McIntyre et al.
7 citations
Suicide is a pressing public health issue, with over 700,000 individuals dying each year. Ketamine has emerged as a promising treatment for suicidal thoughts and behaviors (STBs), yet the complex mechanisms underlying ketamine’s anti-suicidal effect are not fully understood. Computational psychiatry provides a promising framework for exploring the dynamic interactions underlying suicidality and...
Frontiers in Psychiatry
June 29, 2023
Winston de la Haye, Geoffrey Walcott, Jordan Eaton et al.
6 citations
The efficacy of psilocybin and other psychedelics as modes of treatment have been demonstrated through clinical trials and other studies in the management of a number of mental illnesses, including some treatment resistant cases. In Psychedelic Assisted Psychotherapy (PAP), psychedelics catalyze or enhance the experience fostered by psychotherapeutic methods. Psychohistoriographic Brief...
Frontiers in Psychiatry
June 27, 2023
Irene Li, Rodney Fong, Molly M. Hagen et al.
25 citations
Introduction Although certain psychedelic agents may soon gain federal approval for use in treating specific psychiatric conditions, the utilization of such therapies in clinical practice will depend largely on the attitudes of healthcare providers. Therefore, this study assesses the current attitudes, knowledge, exposure, and acceptance of psychedelics and psychedelic-assisted therapies...
Frontiers in Psychiatry
June 26, 2023
Simon Zhornitsky, Henrique Nunes Pereira Oliva, Laura A. Jayne et al.
12 citations
Background Ketamine and psychedelics have abuse liability. They can also induce “transformative experiences” where individuals experience enhanced states of awareness. This enhanced awareness can lead to changes in preexisting behavioral patterns which could be beneficial in the treatment of substance use disorders (SUDs). Preclinical and clinical studies suggest that ketamine and psychedelics...
Frontiers in Psychiatry
June 21, 2023
Lily A. L. Martin, David Melchert, Monika Knack et al.
4 citations
Introduction: Basic self-disorders on the one hand and motor symptoms on the other hand are discussed as endophenotypes of schizophrenia psychopathology. However, the systematic interaction between motor symptoms and the self-experience of patients is rarely studied. Methods: In a previous study we defined motor markers of schizophrenia via a data-driven analysis of patients' gait patterns. In...
Frontiers in Psychiatry
June 20, 2023
Johannes T. Reckweg, Cees van Leeuwen, Cécile Henquet et al.
86 citations
Background Treatment-resistant depression (TRD) is a substantial public health burden, but current treatments have limited effectiveness. The aim was to investigate the safety and potential antidepressant effects of the serotonergic psychedelic drug 5-MeO-DMT in a vaporized formulation (GH001) in adult patients with TRD. Methods The Phase 1 part ( n = 8) of the trial investigated two single...
Frontiers in Psychiatry
June 16, 2023
Sean Matthew Viña, Amanda Layne Stephens
18 citations
This study aims to understand the relationship between Lifetime Classic Psychedelic Use (LCPU), employment status, and weekly work hours on levels of psychological distress. The data used for this analysis is pooled from the National Survey of Drug Use and Health (NSDUH) from 2008–2019 and includes a sample size of 484,732 individuals. The findings suggest that LCPU and being employed are...
Frontiers in Psychiatry
June 12, 2023
Rayyan Zafar, Maxim Siegel, Rebecca Harding et al.
95 citations
Psychedelic therapy has witnessed a resurgence in interest in the last decade from the scientific and medical communities with evidence now building for its safety and efficacy in treating a range of psychiatric disorders including addiction. In this review we will chart the research investigating the role of these interventions in individuals with addiction beginning with an overview of the...
Frontiers in Psychiatry
May 18, 2023
Tigran Makunts, Diane Dahill, Lisa Jerome et al.
6 citations
3,4-Methylenedioxymethamphetamine (MDMA) is currently being investigated as an adjunctive treatment to therapy for posttraumatic stress and other anxiety related disorders in clinical trials. Within the next few years MDMA-assisted therapy is projected for approval by regulatory authorities. MDMA's primary mechanism of action includes modulation of monoamine signaling by increasing release and...
Frontiers in Psychiatry
April 25, 2023
Rachael Grazioplene, Calvin Bohner, Giuliana DePalmer et al.
27 citations
Background Psilocybin may help treat obsessive–compulsive disorder (OCD). To date, only one open-label study of psilocybin for OCD exists, necessitating further investigation with a randomized controlled design. The neural correlates of psilocybin’s effects on OCD have also not been studied. Objectives This first-of-its-kind trial aims to evaluate the feasibility, safety, and tolerability of...
Frontiers in Psychiatry
April 14, 2023
Jennifer L. Jones
4 citations
BackgroundAlcohol and other substance use disorders are commonly associated with post-traumatic stress disorder (PTSD), and the presence of these comorbidities is associated with worse treatment outcomes. Additionally, disparities in substance and PTSD prevalence have been associated with minority races and ethnicities, and minorities have been shown to be less likely to engage in treatment....
Frontiers in Psychiatry
April 5, 2023
Sharday Mosurinjohn, Leor Roseman, Manesh Girn
54 citations
Contemporary research on serotonergic psychedelic compounds has been rife with references to so-called ‘mystical’ subjective effects. Several psychometric assessments have been used to assess such effects, and clinical studies have found quantitative associations between ‘mystical experiences’ and positive mental health outcomes. The nascent study of psychedelic-induced mystical experiences,...
Frontiers in Psychiatry
March 23, 2023
Xiyao Xie, Teresa Bertram, Saša Zorjan et al.
IntroductionSocial reappraisal, during which one person deliberately tries to regulate another’s emotions, is a powerful cognitive form of social emotion regulation, crucial for both daily life and psychotherapy. The neural underpinnings of social reappraisal include activity in the default mode network (DMN), but it is unclear how social processes influence the DMN and thereby social...
Frontiers in Psychiatry
March 14, 2023
Jonathan Brett, Elizabeth Knock, Paul Liknaitzky et al.
16 citations
Methamphetamine use disorder is a chronic relapsing condition associated with substantial mental, physical, and social harms and increasing rates of mortality. Contingency management and psychotherapy interventions are the mainstays of treatment but are modestly effective with high relapse rates, while pharmacological treatments have shown little to no efficacy. Psilocybin-assisted...
Frontiers in Psychiatry
March 2, 2023
Hangyu Li, Wanli Qin, Nannan Li et al.
BackgroundAs a common clinical symptom, insomnia has a high incidence of combined mental illness and it is also a risk factor for the development of depression, anxiety and suicide. As a new concept in the field of health in recent years, mindfulness therapy can improve insomnia, anxiety and depression, which is a new way to solve such diseases.ObjectiveThis study aims to systematically...
Frontiers in Psychiatry
February 23, 2023
Rammohan Shukla, Mohamed Sherif, Mostafa Z. Khalil et al.
1 citation
Introduction Synapses and spines play a significant role in major depressive disorder (MDD) pathophysiology, recently highlighted by the rapid antidepressant effect of ketamine and psilocybin. According to the Bayesian brain and interoception perspectives, MDD is formalized as being stuck in affective states constantly predicting negative energy balance. To understand how spines and synapses...
Frontiers in Psychiatry
February 20, 2023
Chelsea R. Miller, Bradley G. Burk, Rachel E. Fargason et al.
16 citations
Background Cannabis (Δ 9 -THC) is the most commonly consumed illicit drug. The Agricultural Improvement Act of 2018 removed hemp, a strain of Cannabis sativa , as a controlled substance. This law allowed the plant to be processed into its components, which contain <0.3% Δ 9 -THC. As a result, delta-8-tetrahydrocannabinol (Δ 8 -THC), a federally unregulated substance, grew in popularity in 2020....
Frontiers in Psychiatry
February 10, 2023
Muhammad Ishrat Husain, Nicole Ledwos, Elise Fellows et al.
47 citations
Introduction Current treatment options for major depressive disorder (MDD) have limited efficacy and are associated with adverse effects. Recent studies investigating the antidepressant effect of serotonergic psychedelics—also known as classic psychedelics—have promising preliminary results with large effect sizes. In this context, we conducted a review of the putative neurobiological...
Frontiers in Psychiatry
February 9, 2023
Kees Kramers, Arnt Schellekens, Metten Somers et al.
119 citations
Background Psychedelic-assisted therapy [e.g., with lysergic acid diethylamide (LSD)] has shown promising results as treatment for substance use disorders (SUDs). Previous systematic reviews assessing the efficacy of psilocybin in SUDs only included clinical trials conducted in the last 25 years, but they may have missed clinical trials assessing the efficacy of psilocybin that were conducted...
Frontiers in Psychiatry
February 9, 2023
Orli Dahan
14 citations
The subjective childbirth experience is crucial from a public health standpoint. There is a correlation between a negative childbirth experience and a poor mental state after birth, with effects that go far beyond the postpartum (PP) period. This paper offers a new approach as to how birthing experiences, and birth in general, can be navigated. The theory of set and setting proves that...